I might add that Brelinta is used mostly with aspirin in patients who have had recent stents placed, dvt’s, and patients who have had aortic valve via TAVR, etc. In other words it’s use is indicated in more acute patient episodes, and 208, imho seems to be intended for MACE prevention for the long term via a different MOA. Prescriptions for Brelinta are much more costly than 208 is expected to be. With this agent a bleed can always occur, and at ths juncture their does not appear to exist a drug to reverse any hemorrhage occurring secondary to its use.

One must be careful of its use for any person with an active life style that may fall or become injured effecting an internal or external bleed. Bleeding out is always a concern in these cases.

A small bio ( PTLA ) is on the cusp of having the FDA consider an agent that is hoped to be very effective in reversing bleeds occurring  secondary to the use of Brelinta type agents. Just saying...